Skip to Content

Posts tagged with "Press Coverage"

  • Drug Development

    Optimistic Stem Cell Quotes

    How does the press cover stem cell work? You probably already know the answer to that one, but here’s proof: this paper examines the media coverage from 2010 to 2013, and finds that “highly optimistic” timelines for translation to the clinic are the rule. Unfortunately, they also find that quotes from scientists are the main… Read More
  • Press Coverage

    A Pharma Expert Weighs In

    In case you were wondering, Chuck Norris does not know what he’s talking about when he talks about drug discovery and development. In other news, I don’t know what I’m talking about when I talk about martial arts or tv/movie production. But I’m not trying to tell Chuck Norris about those things, now, am I?… Read More
  • Press Coverage

    The New York TImes on Drug Discovery

    The New York Times Magazine has a piece on the current problems with drug discovery. I was interviewed by the author, and get I quoted at one point. Nothing in the article will amaze any regular reader here, but it’s probably the first time many of the magazine’s readership are hearing about many of these… Read More
  • Clinical Trials

    Studies Show? Not So Fast.

    Yesterday’s post on yet another possible Alzheimer’s blood test illustrates, yet again, that understanding statistics is not a strength of most headline writers (or most headline readers). I’m no statistician myself, but I have a healthy mistrust of numbers, since I deal with the little rotters all day long in one form or another. Read More
  • Cancer

    Is Palbociclib Promising? Or Not?

    Here’s a good test for whatever news outlets you might be using for biotech information. How are they handling Pfizer’s release of palbociclib information from the AACR meeting over the weekend? Do a news search for the drug’s name, and you’ll see headline after headline. Many of them include the phrase “Promising Resu… Read More
  • Cancer

    For Immediate Rewording. Uh, Release.

    Here’s a nice look at why you should always think about the source of the financial and business information you read. It details the response to a recent Pfizer press release about palbociclib, a CDK inhibitor that’s in late clinical trials. Someone at The Wall Street Journal wrote that it had “the potential. . .to… Read More
  • Chemical News

    The West Virginia Formaldehyde Claim Is Nonsense

    This morning I heard reports of formaldehyde being found in Charleston, West Virginia water samples as a result of the recent chemical spill there. My first thought, as a chemist, was “You know, that doesn’t make any sense”. A closer look confirmed that view, and led me to even more dubious things about this news… Read More
  • Chemical News

    A Long Fight Over Allegations of Fraud

    Here’s a long article from the Raleigh News and Observer (part one and part two) on the Eaton/Feldheim/Franzen dispute in nanoparticles, which some readers may already be familiar with (I haven’t covered it on the blog myself). The articles are clearly driven by Franzen’s continued belief that research fraud has been committed, an… Read More
  • Press Coverage

    More Worthless Press Releases

    To go along with those nominations for worst press releases of the year, here’s a roundup of stinkers in the biomedical field. And they do reek. I got some of these in my in-box as well, and I probably got even more of them than I remember. Sad to say, PR material (or at least… Read More
  • Press Coverage

    Worst Scientific Press Releases of 2013?

    In the same spirit as Adam Feuerstein’s “Worst Biotech CEO” nominations from the other day, here’s Michael Eisen asking what the worst scientific press releases of the year were. Most Overhyped and Most Egregious Failure to Cite Earlier Work are two especially hard categories to win. If you have some examples that particular… Read More
...234...